(2022) conducted phase II trials to assess the efficacy of combination therapy involving anti-CD30 directed CAR-T cells and anti PD-1 antibodies in cases of relapsed and refractory CD30+ lymphomas, including Hodgkin lymphoma (HL), gray zone lymphoma (GZL), and angioimmunoblastic T-cell lymphoma (AITL) of various grades. This evidence concerns the gene TNFRSF8 and angioimmunoblastic T-cell lymphoma.